The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 28, 2021

Filed:

Aug. 12, 2016
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Bayer Pharma Aktiengesellschaft, Berlin, DE;

Inventors:

Luc De Waal, Boston, MA (US);

Matthew Meyerson, Boston, MA (US);

Heidi Greulich, Boston, MA (US);

Monica Schenone, Boston, MA (US);

Alex Burgin, Cambridge, MA (US);

Xiaoyun Wu, Cambridge, MA (US);

Ulrike Sack, Monheim Am Rhein, DE;

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/50 (2006.01); G01N 33/574 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
A61K 31/50 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01); G01N 33/57488 (2013.01); A61K 2300/00 (2013.01); G01N 2333/916 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).


Find Patent Forward Citations

Loading…